{'output': [['NanoString Technologies, Inc.', 'COMP', 'Provide', 'life science tools', 'PRODUCT'], ['NanoString Technologies, Inc.', 'COMP', 'Offer', 'nCounter® Analysis System', 'PRODUCT'], ['nCounter® Analysis System', 'PRODUCT', 'Employ', 'in life sciences research', 'EVENT'], ['nCounter® Analysis System', 'PRODUCT', 'Cited', 'in more than 1,820 peer-reviewed publications', 'EVENT'], ['nCounter® Analysis System', 'PRODUCT', 'Facilitate', 'a wide variety of basic research and translational medicine applications', 'EVENT'], ['Prosigna® Breast Cancer Prognostic Gene Signature Assay', 'PRODUCT', 'FDA 510(k) cleared', 'for use as a prognostic indicator for distant recurrence of breast cancer', 'EVENT'], ['NanoString Technologies, Inc.', 'COMP', 'Collaborate', 'with biopharmaceutical companies', 'SECTOR'], ['NanoString Technologies, Inc.', 'COMP', 'Help', 'to realize the promise of precision oncology', 'CONCEPT'], ['NanoString Technologies, Inc.', 'COMP', 'Shift resources', 'to its high-impact platform-development programs', 'EVENT'], ['NanoString Technologies, Inc.', 'COMP', 'Eliminate', 'approximately 30 positions', 'EVENT'], ['NanoString Technologies, Inc.', 'COMP', 'Expect', 'that its existing cash on-hand will be sufficient to fund its operations through mid-2019', 'EVENT'], ['NanoString Technologies, Inc.', 'COMP', 'Enter', 'into a $15 million revolving credit facility and a $40 million “at-the-market” facility agreement', 'EVENT'], ['NanoString Technologies, Inc.', 'COMP', 'Give', 'a corporate update at the JP Morgan Healthcare conference', 'EVENT'], ['NanoString Technologies, Inc.', 'COMP', 'Provide', 'preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2017', 'EVENT'], ['Product and service revenue for fiscal year 2017', 'ECON_INDICATOR', 'Expected', 'to be approximately $72 million', 'EVENT'], ['Product and service revenue for the fourth quarter of 2017', 'ECON_INDICATOR', 'Expected', 'to be approximately $21 million', 'EVENT'], ['Total revenue for fiscal year 2017', 'ECON_INDICATOR', 'Expected', 'to be in the range of $113 to $115 million', 'EVENT'], ['Cash, cash equivalents and short-term investments', 'ECON_INDICATOR', 'Of approximately', '$82 million at December 31, 2017', 'EVENT'], ['Approximately 125 nCounter ® Analysis Systems', 'ECON_INDICATOR', 'Sold', 'in 2016', 'EVENT'], ['Installed base of approximately 605 nCounter Analysis Systems', 'ECON_INDICATOR', 'At December 31, 2017', 'EVENT'], ['More than 1,820 cumulative peer-reviewed publications', 'ECON_INDICATOR', 'Of studies based on nCounter technology', 'EVENT'], ['Brad Gray', 'PERSON', 'Said', 'While 2017 was a challenging year', 'EVENT'], ['Brad Gray', 'PERSON', 'Believe', 'that actions we have taken helped to stabilize the business in the fourth quarter', 'EVENT'], ['Brad Gray', 'PERSON', 'Achieved', 'both solid SPRINT sales and record consumables revenue during the fourth quarter', 'EVENT'], ['Brad Gray', 'PERSON', 'Taken actions', 'to resource key development programs, extend the runway provided by our existing cash, and expand our access to additional capital', 'EVENT']]}